The Group

Yincheng International Holding Announces 2022 Interim Results

Retrieved on: 
Friday, August 26, 2022
COVID-19, Yoy, GFA, City, RMB, Social responsibility, Group, The Group, Lender option borrower option, ASP, Industry, Bank, Period, PRC

HONG KONG, Aug 26, 2022 - (ACN Newswire) - An established property developer in the PRC focusing on developing quality residential properties in the Yangtze River Delta Megalopolis for customers of all ages, Yincheng International Holding Co., Ltd. ("Yincheng International Holding" or the "Company", together with its subsidiaries, the "Group", Stock code: 1902.HK) is pleased to announce its unaudited consolidated interim results for the six months ended 30 June 2022 (the "Period").

Key Points: 
  • HONG KONG, Aug 26, 2022 - (ACN Newswire) - An established property developer in the PRC focusing on developing quality residential properties in the Yangtze River Delta Megalopolis for customers of all ages, Yincheng International Holding Co., Ltd. ("Yincheng International Holding" or the "Company", together with its subsidiaries, the "Group", Stock code: 1902.HK) is pleased to announce its unaudited consolidated interim results for the six months ended 30 June 2022 (the "Period").
  • During the Period, the Group's revenue increased by approximately 20.9% YoY to approximately RMB 4.58 billion.
  • Net profit margin remained roughly the same as that from the same period last year at approximately 7.3%.
  • During the Period, the Group recorded contracted sales of approximately RMB6.57 billion, which drop was in line with the overall trend amongst its peers.

Q P Group Announces Record-high 2022 Interim Results

Retrieved on: 
Friday, August 26, 2022
People, COVID-19, CEO, Awareness, Republic, Solution, OEM, Board, Company, Group, The Group, Growth, Board of directors, Marketing, PRC

HONG KONG, Aug 26, 2022 - (ACN Newswire) - Q P Group Holdings Limited ("Q P Group" or the "Group"; Stock code: 1412), one of the leading manufacturers of paper-based tabletop games and paper-based greeting cards in the People's Republic of China (the "PRC"), recorded a total revenue of approximately HK$657.8 million, representing a year-on-year increase of approximately 11.6% for the six months ended 30 June 2022 ("6M2022" or the "Period").

Key Points: 
  • HONG KONG, Aug 26, 2022 - (ACN Newswire) - Q P Group Holdings Limited ("Q P Group" or the "Group"; Stock code: 1412), one of the leading manufacturers of paper-based tabletop games and paper-based greeting cards in the People's Republic of China (the "PRC"), recorded a total revenue of approximately HK$657.8 million, representing a year-on-year increase of approximately 11.6% for the six months ended 30 June 2022 ("6M2022" or the "Period").
  • Q P Group will make determined efforts to promote the mutually beneficial business model of QPMN to potential partners including brand owners, enterprises, designers and organisations.
  • In addition, Q P Group is developing a comprehensive supply chain in Vietnam to expand production capacity and diversify operational risk.
  • About Q P Group Holdings Limited (Stock code: 1412)
    Established in Hong Kong in 1985, Q P Group is one of the leading paper-based tabletop games and paper-based greeting cards manufacturers in the PRC, with production sites in Dongguan and Heshan.

Chu Kong Shipping Announces 2022 Interim Results, Profit Attributable to the Equity Holders of the Company Significantly Increases by 110.6% to HK$54.9 Million

Retrieved on: 
Thursday, August 25, 2022
Pearl River Delta, COVID-19, The Company, ASEAN, PRD, Central Kowloon Route, Belt and Road Initiative, Awareness, Engineering, Guangzhou Baiyun International Airport, City, Solution, Belt, Maintenance, Pressure, Guangdong-Hong Kong-Macau Greater Bay Area, Seemabaddha, TEU, Social responsibility, Quarantine, Water, Company, Central Piers, Oriental Pearl, News, The Group, Holding, Face, International airport, Acquisition, Growth, Transport, Efficiency, Chu Kong Passenger Transport, Tutoring, Warehouse, Airline, Period, Hong Kong International Airport, Group

Profit for the Period amounted to HK$61.7 million (1H 2021: HK$39.7 million), representing an increase of 55.4% over the same period last year.

Key Points: 
  • Profit for the Period amounted to HK$61.7 million (1H 2021: HK$39.7 million), representing an increase of 55.4% over the same period last year.
  • Profit attributable to the equity holders of the Company amounted to HK$54.9 million (1H 2021: HK$26.1 million), representing an increase of 110.6% over the same period last year.
  • Chu Kong Shipping is a listed company incorporated in Hong Kong held by Chu Kong Shipping Enterprises (Holdings) Company Limited and subject to Guangdong Provincial Port & Shipping Group Company Limited.
  • Chu Kong Shipping is also one of the largest operators of inland terminal and logistics service in the PRD.

Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA

Retrieved on: 
Wednesday, August 24, 2022
Ibrutinib, Investigational New Drug, The Company, Rheumatoid arthritis, Safety, CD22, Research, RA, Central nervous system, Degenerative disease, IND, Smoking, SLE, Mab, Disease, EBV, Multiple sclerosis, Epstein–Barr virus infection, R, National Medical Products Administration, Thirteenth, Asthma, B-cell lymphoma, Twelfth, NHL, NMPA, Antibody, Non-Hodgkin lymphoma, Neuromyelitis optica spectrum disorder, Company, Therapy, Lupus, PV, NMOSD, The Group, MS, Optic nerve, Optic neuritis, Spinal cord, Drug discovery, SM03, BTK, Trial of the century, Pemphigus, Pharmaceutical industry, Phase

The IND approval would enable the Company to initiate the Phase II/III clinical study in China to evaluate the efficacy and safety of SN1011 for the treatment of NMOSD in China.

Key Points: 
  • The IND approval would enable the Company to initiate the Phase II/III clinical study in China to evaluate the efficacy and safety of SN1011 for the treatment of NMOSD in China.
  • SN1011 differentiates from existing BTK inhibitors currently available in the market, such as Ibrutinib, in terms of mechanism of action, affinity, selectivity and safety.
  • Currently, four IND applications of SN1011 for the treatment of SLE, PV, MS and NMOSD have been approved by NMPA respectively.
  • SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases.

REDSUN SERVICES's 2022 Interim Profit Attributable to Equity Shareholders Increases 15.8% to RMB69.3 million

Retrieved on: 
Tuesday, August 23, 2022
Cloud, Management, GFA, City, Engineering, CIA, Maintenance, FTSE Russell, Compliance, The Group, Yangtze Delta, FTSE Global Equity Index Series, Purchasing Managers' Index, Review, Efficiency, Fossil fuel, Cryptocurrency, Risk management, Group

-- The Group's revenue was RMB553.9 million, representing an increase of 4.7% compared with the same period last year.

Key Points: 
  • -- The Group's revenue was RMB553.9 million, representing an increase of 4.7% compared with the same period last year.
  • -- Profitability remained stable with a gross profit margin of 27.2%, while profit attributable to equity shareholders was RMB69.3 million, an increase of 15.8%.
  • Overall gross profit reached RMB150.8 million with a gross profit margin of 27.2%.
  • Profit attributable to equity shareholders was RMB69.3 million, an increase of 15.8% as compared with the same period last year.

Peijia Medical Announces 2022 Interim Results: TaurusOne(R) and TaurusElite(R) Repeatedly Sets New Monthly Highs in Implantation Volume

Retrieved on: 
Monday, August 22, 2022
AIS, Technology, ICAD, Hotel manager, National Heart Valve Disease Awareness Day, Bleeding, Journal of NeuroInterventional Surgery, City, Solution, Launch, Highlife, FIM, Board, AR, Physician, BD, Hospital, NMPA, Company, Stroke, Group, The Group, Uncertainty, COVID-19, TAVR, Growth, Industry, Marketing, Adoption, Patient, Fine chemical, Medical device, Pharmaceutical industry, Renewable energy, Video game

The total implantation volume of the six months ended June 30, 2022 has far exceeded that of the whole year of 2021.

Key Points: 
  • The total implantation volume of the six months ended June 30, 2022 has far exceeded that of the whole year of 2021.
  • In the first half of 2022, the Group continued expanding its share in the sizable hemorrhagic market, constantly consolidating its leading position in the neurointerventional industry.
  • As of July 31, 2022, the products of the Group entered 209 hospitals, repeatedly setting new monthly highs in implantation volume.
  • For the seven months ended July 31, 2022, the total implantation volume reached close to 650 units, more than twice the implantation volume for the whole year 2021.

IVD Medical Announces 2022 Interim Results

Retrieved on: 
Sunday, August 21, 2022
People, COVID-19, Plasmin, Research, Government, Thrombosis, Awareness, Republic, Point-of-care testing, R, Sale, Maintenance, Board, Pharmacy and Poisons Board, Diagnosis, IVD, Mass spectrometry, Hospital, Quarantine, Fibrinolysis, Thrombomodulin, The Group, Microbiology, Industry, Growth, Health insurance, Pharmaceutical industry, Risk management, Fine chemical, Sysmex Corporation, Group, PRC

HONG KONG, Aug 22, 2022 - (ACN Newswire) - IVD Medical Holding Limited ("IVD Medical" or the "Group"), a leading distributor of In Vitro Diagnostic ("IVD(1)") products in the PRC, has announced its interim results for the six months ended 30 June 2022 ("Period").

Key Points: 
  • HONG KONG, Aug 22, 2022 - (ACN Newswire) - IVD Medical Holding Limited ("IVD Medical" or the "Group"), a leading distributor of In Vitro Diagnostic ("IVD(1)") products in the PRC, has announced its interim results for the six months ended 30 June 2022 ("Period").
  • Mr. Ho Kuk Sing, Chairman of IVD Medical, said, "In 2022, although the business environment of the medical industry has been tough under the pandemic, we have worked hard to overcome challenges and optimize our business operations.
  • The Group's self-branded IVD reagents were manufactured by Suzhou DiagVita Biotechnology Co., Ltd. and Bazoe Medical Co., Ltd., and the Group's IVD analysers were produced by its equipment manufacturers, IVD Medical Equipment (Shanghai) Ltd. and Langmai Biotechnology (Shandong) Co., Ltd.
  • IVD Medical Holding Limited ("IVD Medical" or the "Group") is a leading distributor of IVD products in the PRC.

Hatten Land Signs Partnership Agreement to Launch The World's First-of-its-Kind Mobile Legends: Bang Bang, Southeast Asia's Top Game with 100 Million Monthly Active Users, Themed Integrated Esports Hub in Melaka at ElementX

Retrieved on: 
Thursday, August 18, 2022
Telephone, SINGAPORE, Association, UOB-Kay Hian, Lead, Mobile Legends: Bang Bang, UNESCO, Senior, COVID-19, Population, Ecosystem, Growth, Catalist, Continuous Computing, Go, Compliance, Marketing, Southeast Asian Games, Company, Education, MSC 2019, SEA Games 3, Mining, Partnership, Dato, Tourism, RADIUS, The Group, Sponsor, SGX, MLBB, SEA, Video game, Amusement park, Health insurance, Group, Metaverse

Since the 2019 Southeast Asian Games ("SEA Games"), Mobile Legends: Bang Bang has been featured in successive SEA Games as a medal event.

Key Points: 
  • Since the 2019 Southeast Asian Games ("SEA Games"), Mobile Legends: Bang Bang has been featured in successive SEA Games as a medal event.
  • According to Sensor Tower Store Intelligence estimates, total gross revenue of Mobile Legends: Bang Bang surpassed US$500 million in 2020 with user spending of US$214.1 million in 2019.
  • Malaysia has proven to be Mobile Legends' most lucrative market globally, with players there spending US$87.5 million in the game, or 17 percent of total revenue.
  • Mobile Legends: Bang Bang has experienced explosive growth globally with Southeast Asia being its key revenue market since its launch in 2016.

China Online Education Group Announces Engagement of Marcum Bernstein & Pinchuk LLP, a U.S. Auditor, as the Company's Independent Registered Public Accounting Firm

Retrieved on: 
Monday, August 15, 2022
Online, U.S. Securities and Exchange Commission, Forward-looking statement, NYSE, SEC, Learning, Security (finance), Disagreement, The Company, Company, Mission statement, MBP, COE, The Group, Private Securities Litigation Reform Act, Annual report, Student, Terminology, PricewaterhouseCoopers, Tutoring

This press release contains statements that may constitute "forward-looking" statements which are made pursuant to the "safe harbor" provisions of the U.S.

Key Points: 
  • This press release contains statements that may constitute "forward-looking" statements which are made pursuant to the "safe harbor" provisions of the U.S.
  • These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "future," "intends," "plans," "believes," "estimates," "likely to," and similar statements.
  • China Online Education Group (NYSE: COE) is a global online education platform with core expertise in English education.
  • The Company's online and mobile education platforms enable students to take live interactive English lessons on demand.

I-RES completes acquisition of Tara View, Merrion Road, Dublin 4

Retrieved on: 
Monday, August 15, 2022
Trust, Industry, Legislation, Growth, Investment, Hospital, Elm Park, Group, Merrion Road, Dalata Hotel Group, City centre, IRES, Government, Schoolyard, Company, School, Acquisition, Real estate investment trust, The Group, COVID-19, Employment, Angelo Gordon, Euronext Dublin, VAT, Sales, Property management

I-RES completes acquisition of Tara View, Merrion Road, Dublin 4

Key Points: 
  • I-RES completes acquisition of Tara View, Merrion Road, Dublin 4
    Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • I-RES completes acquisition of Tara View, Merrion Road, Dublin 4
    Dublin | 15 August: Irish Residential Properties REIT plc ("I-RES" or the "Company") is pleased to announce it has completed the acquisition of 69 new residential homes at Tara View, Merrion Road, Dublin 4 (formerly known as Project Merrion).
  • Tara View is a prime waterfront development located adjacent to the Elm Park development (where the Company owns 194 apartments) in Dublin 4, Irelands premier residential address.
  • These excellent homes, many with excellent views across Dublin Bay and the Dublin mountains, will appeal to a range of residents.